AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The companys products in pipeline include NEST platform technology products for stomach, breast, colorectal, lung, and solid cancers.
Abclon also offers peptide and protein for antibody development; monoclonal antibody service for various antigens comprising peptide, protein, and recombinant proteins; polyclonal antibodes, protein kits and antibody drug development services.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”174900.KQ” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
In Nov 2016, AbClon grants Chinese development rigts of AC101, to Shanghai Hanlius Biotech, under the agreement, Hanlius paid US$1 Mn as an upfront and US$15.5 Mn in commission and royalty. Shanghai Hanlius Biotech is a joint venture established by Shanghai Fosun Pharmaceutical and Henlius Biopharmaceutical in 2009.
In June 2013, Affibody AB and AbClon signed a license agreement regarding the use of Affibodys proprietary technology platforms: Affibodyë molecules and AlbumodTM for use in combination with AbClons proprietary and/or generic anti-cancer antibodies.
Recover your password.
A password will be e-mailed to you.